Stay updated with breaking news from Astrazeneca Evusheld. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The new variants popping up might mean we see more virus transmission — and more infections. But the shots still do a good job keeping people safe from severe infections, hospitalizations and death.
Some rather alarming headlines recently circulated about the newest members of the omicron family. “Nightmare COVID variant,” read one. “The most immune-evasive COVID variants yet.” Or, as one would-be pandemic
Middle-East Arab News and Opinion - Asharq Al-Awsat is the world’s premier pan-Arab daily newspaper, printed simultaneously each day on four continents in 14 cities
AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been approved in the European Union (EU)